Please use this identifier to cite or link to this item:
https://olympias.lib.uoi.gr/jspui/handle/123456789/23116Full metadata record
| DC Field | Value | Language |
|---|---|---|
| dc.contributor.author | Kunschner, L. J. | en |
| dc.contributor.author | Fine, H. | en |
| dc.contributor.author | Hess, K. | en |
| dc.contributor.author | Jaeckle, K. | en |
| dc.contributor.author | Kyritsis, A. P. | en |
| dc.contributor.author | Yung, W. K. | en |
| dc.date.accessioned | 2015-11-24T19:30:32Z | - |
| dc.date.available | 2015-11-24T19:30:32Z | - |
| dc.identifier.issn | 0735-7907 | - |
| dc.identifier.uri | https://olympias.lib.uoi.gr/jspui/handle/123456789/23116 | - |
| dc.rights | Default Licence | - |
| dc.subject | Adult | en |
| dc.subject | Aged | en |
| dc.subject | Antineoplastic Agents/administration & dosage/adverse effects/*therapeutic use | en |
| dc.subject | Brain Neoplasms/*drug therapy | en |
| dc.subject | Carbamates/administration & dosage/adverse effects/*therapeutic use | en |
| dc.subject | Disease-Free Survival | en |
| dc.subject | Female | en |
| dc.subject | Glioma/*drug therapy | en |
| dc.subject | Humans | en |
| dc.subject | Infusions, Intravenous | en |
| dc.subject | Male | en |
| dc.subject | Maximum Tolerated Dose | en |
| dc.subject | Middle Aged | en |
| dc.subject | Neoplasm Recurrence, Local/*drug therapy | en |
| dc.subject | Pyrazines/administration & dosage/adverse effects/*therapeutic use | en |
| dc.subject | Pyridines/administration & dosage/adverse effects/*therapeutic use | en |
| dc.subject | Survival Rate | en |
| dc.subject | Thrombocytopenia/chemically induced | en |
| dc.subject | Treatment Outcome | en |
| dc.title | CI-980 for the treatment of recurrent or progressive malignant gliomas: national central nervous system consortium phase I-II evaluation of CI-980 | en |
| heal.type | journalArticle | - |
| heal.type.en | Journal article | en |
| heal.type.el | Άρθρο Περιοδικού | el |
| heal.identifier.secondary | http://www.ncbi.nlm.nih.gov/pubmed/12449727 | - |
| heal.language | en | - |
| heal.access | campus | - |
| heal.recordProvider | Πανεπιστήμιο Ιωαννίνων. Σχολή Επιστημών Υγείας. Τμήμα Ιατρικής | el |
| heal.publicationDate | 2002 | - |
| heal.abstract | OBJECTIVE: The purpose of this phase I/II trial was to determine the maximal tolerated dose of CI-980, and determine efficacy against malignant glioma. BACKGROUND: The CI-980 is a synthetic mitosis inhibitor that acts via the colchicine binding site on tubulin. Broad in vitro activity has been seen in a variety of human and murine tumor models. Phase I studies have demonstrated schedule dependent toxicity of CI-980. Dose-limiting toxicity was neurologic when CI-980 was given as a 24-hr infusion and hematologic when given over 72 hr at higher doses. METHODS: Twenty-four patients ages 29-65 entered this study. Six patients were treated on the phase I arm at three escalating dose levels ranging from 10.5 to 13.5 mg/m2, given over 72 hr. Eighteen patients were then treated at the highest tolerated dose, 13.5 mg/m2 per cycle. Treatment response was based on serial MRI imaging characteristics. RESULTS: The phase II study was stopped at the end of the first stage due to poor treatment response. There were no partial or complete responses, (0/24) 95% CI = 0-14%. Four patients (4/24) had a best treatment response of stable disease/no change. Median time to progression for all patients was 6.4 weeks (95% CI: 6-9 weeks). Dose-limiting toxicity was grade 3-4 granulocytopenia. Three episodes of neurotoxicity manifested by a moderate cerebellar dysfunction were seen. CONCLUSIONS: These results fail to demonstrate the significant activity of CI-980 against recurrent glioma. | en |
| heal.journalName | Cancer Invest | en |
| heal.journalType | peer-reviewed | - |
| heal.fullTextAvailability | TRUE | - |
| Appears in Collections: | Άρθρα σε επιστημονικά περιοδικά ( Ανοικτά) - ΙΑΤ | |
Files in This Item:
There are no files associated with this item.
This item is licensed under a Creative Commons License
